Fujian Wanchen Biotechnology Co Ltd
SZSE:300972
Fujian Wanchen Biotechnology Co Ltd
SZSE:300972
Price:
182.03
CNY
-0.89%
Market Cap:
¥34.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Fujian Wanchen Biotechnology Co Ltd
SZSE:300972
|
CN |
Income Statement
Earnings Waterfall
Fujian Wanchen Biotechnology Co Ltd
Fujian Wanchen Biotechnology Co Ltd
Income Statement
Fujian Wanchen Biotechnology Co Ltd
Fujian Wanchen Biotechnology Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
6
|
8
|
6
|
5
|
6
|
5
|
5
|
4
|
4
|
4
|
6
|
11
|
15
|
29
|
37
|
43
|
52
|
51
|
56
|
0
|
0
|
|
| Revenue |
327
N/A
|
450
+38%
|
417
-7%
|
399
-4%
|
371
-7%
|
435
+17%
|
439
+1%
|
462
+5%
|
537
+16%
|
549
+2%
|
1 194
+117%
|
2 564
+115%
|
5 091
+99%
|
9 294
+83%
|
13 362
+44%
|
17 992
+35%
|
25 006
+39%
|
32 329
+29%
|
38 319
+19%
|
43 996
+15%
|
48 278
+10%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(236)
|
(327)
|
(326)
|
(352)
|
(351)
|
(390)
|
(403)
|
(400)
|
(431)
|
(462)
|
(1 017)
|
(2 291)
|
(4 662)
|
(8 431)
|
(12 174)
|
(16 219)
|
(22 449)
|
(28 852)
|
(34 201)
|
(39 186)
|
(42 790)
|
|
| Gross Profit |
91
N/A
|
123
+35%
|
91
-26%
|
47
-48%
|
20
-57%
|
45
+122%
|
36
-20%
|
61
+70%
|
106
+73%
|
88
-17%
|
178
+103%
|
273
+53%
|
429
+57%
|
863
+101%
|
1 188
+38%
|
1 773
+49%
|
2 557
+44%
|
3 477
+36%
|
4 118
+18%
|
4 810
+17%
|
5 488
+14%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(13)
|
(20)
|
(20)
|
(9)
|
(11)
|
(13)
|
(4)
|
(16)
|
(17)
|
(43)
|
(107)
|
(275)
|
(536)
|
(909)
|
(1 155)
|
(1 469)
|
(1 867)
|
(2 391)
|
(2 623)
|
(2 805)
|
(2 845)
|
|
| Selling, General & Administrative |
(17)
|
(21)
|
(23)
|
(26)
|
(26)
|
(26)
|
(27)
|
(26)
|
(30)
|
(53)
|
(113)
|
(278)
|
(537)
|
(899)
|
(1 166)
|
(1 491)
|
(1 897)
|
(2 331)
|
(2 703)
|
(2 899)
|
(2 977)
|
|
| Research & Development |
(0)
|
(0)
|
0
|
(0)
|
(2)
|
(2)
|
0
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(1)
|
(4)
|
(4)
|
(4)
|
(1)
|
(4)
|
(4)
|
(16)
|
|
| Depreciation & Amortization |
0
|
(3)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(8)
|
0
|
0
|
0
|
(151)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
4
|
4
|
4
|
17
|
17
|
18
|
25
|
12
|
14
|
15
|
8
|
5
|
3
|
(1)
|
15
|
26
|
35
|
91
|
84
|
99
|
148
|
|
| Operating Income |
78
N/A
|
104
+34%
|
72
-31%
|
38
-47%
|
9
-77%
|
32
+261%
|
32
+0%
|
45
+40%
|
89
+96%
|
45
-50%
|
71
+59%
|
(3)
N/A
|
(107)
-4 098%
|
(46)
+57%
|
33
N/A
|
304
+817%
|
691
+127%
|
1 086
+57%
|
1 495
+38%
|
2 006
+34%
|
2 643
+32%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(6)
|
(7)
|
(6)
|
(5)
|
(4)
|
(2)
|
(0)
|
0
|
0
|
(1)
|
(5)
|
(11)
|
(19)
|
(27)
|
(37)
|
(40)
|
(40)
|
(37)
|
(40)
|
(41)
|
(39)
|
|
| Non-Reccuring Items |
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
3
|
2
|
(4)
|
(6)
|
(14)
|
(14)
|
(19)
|
(6)
|
(2)
|
1
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(0)
|
(2)
|
(7)
|
(9)
|
(18)
|
(15)
|
3
|
(6)
|
10
|
13
|
|
| Pre-Tax Income |
71
N/A
|
96
+35%
|
65
-32%
|
33
-50%
|
4
-88%
|
29
+634%
|
31
+7%
|
44
+43%
|
88
+97%
|
42
-53%
|
65
+56%
|
(11)
N/A
|
(127)
-1 103%
|
(85)
+33%
|
(19)
+77%
|
232
N/A
|
621
+168%
|
1 032
+66%
|
1 443
+40%
|
1 973
+37%
|
2 618
+33%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
(6)
|
(6)
|
0
|
0
|
(0)
|
(2)
|
(8)
|
(5)
|
(61)
|
(103)
|
(176)
|
(286)
|
(429)
|
(521)
|
(644)
|
(769)
|
|
| Income from Continuing Operations |
71
|
96
|
65
|
33
|
4
|
23
|
25
|
39
|
82
|
42
|
63
|
(18)
|
(132)
|
(146)
|
(123)
|
56
|
335
|
603
|
922
|
1 330
|
1 849
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
6
|
13
|
59
|
86
|
63
|
(6)
|
(132)
|
(278)
|
(310)
|
(420)
|
(566)
|
(785)
|
|
| Net Income (Common) |
71
N/A
|
96
+35%
|
65
-32%
|
33
-50%
|
4
-88%
|
23
+493%
|
25
+8%
|
39
+53%
|
83
+113%
|
48
-42%
|
76
+59%
|
40
-47%
|
(46)
N/A
|
(83)
-79%
|
(129)
-56%
|
(76)
+41%
|
58
N/A
|
294
+409%
|
502
+71%
|
764
+52%
|
1 064
+39%
|
|
| EPS (Diluted) |
0.62
N/A
|
0.84
+35%
|
0.56
-33%
|
0.21
-63%
|
0.02
-90%
|
0.17
+750%
|
0.16
-6%
|
0.25
+56%
|
0.53
+112%
|
0.31
-42%
|
0.5
+61%
|
0.26
-48%
|
-0.3
N/A
|
-0.54
-80%
|
-0.75
-39%
|
-0.5
+33%
|
0.3
N/A
|
1.57
+423%
|
2.49
+59%
|
4.24
+70%
|
5.3
+25%
|
|
Switch to:
Switch to:
See Also
Discover More
